| Outcome Measures: |
Primary: AUCinf: Area Under Plasma Concentration-time Curve From 0 to Infinity in Fasted Condition, The AUCinf of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|AUClast: Area Under Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration in Fasted Condition, The AUClast of verinurad, allopurinol and oxypurinol were assessed in fasted condition as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Cmax: Maximum Observed Plasma Drug Concentration in Fasted State, The Cmax of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period | Secondary: Cmax: Maximum Observed Plasma Drug Concentration, The Cmax of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|AUCinf: Area Under Plasma Concentration-time Curve From 0 to Infinity, The AUCinf of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|AUClast: Area Under Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration, The AUClast of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Tmax: Time to Reach Maximum Observed Plasma Concentration Following Drug Administration, The tmax of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Tlag: Time Delay Between Drug Administration and First Observed Concentration in Plasma, The tlag of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|t½λz: Half-life Associated With Terminal Slope (λz) of Semi-logarithmic Concentration-time Curve, The t½λz of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|λz: Terminal Elimination Rate Constant, The λz of verinurad, allopurinol and oxypurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|CL/F: Apparent Total Body Clearance of Drug Clearance of Drug From Plasma After Extravascular Administration, The CL/F of verinurad and allopurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|MRTinf: Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity, The MRTinf of verinurad and allopurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Vz/F: Apparent Volume of Distribution During Terminal Phase After Extravascular Administration, The Vz/F of verinurad and allopurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Vss/F: Apparent Volume of Distribution at Steady State Following Extravascular Administration, The Vss/F of verinurad and allopurinol were assessed as PK parameters, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Emax, CB: Maximum Percentage Change From Baseline (CB), The Emax, CB in serum uric acid (sUA) concentration (time-matched, Day -1) was assessed as PD parameter., Day -1, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|tEmax, CB: Time of Maximum Percentage CB Change From Baseline (CB), The tEmax, CB in serum uric acid (sUA) concentration (time-matched, Day -1) was assessed as PD parameter., Day -1, Day 1, Day 2, Day 3 and Day 4 of each Treatment Period|Number of Subjects With Adverse Events (AEs) and Serious Adverse Events, The safety of single doses of verinurad and allopurinol were assessed, From screening (Day -28 to -3) until follow-up visit (7 to 14 days post final dose) (approximately 52 to 59 days)
|
